{
    "clinical_study": {
        "@rank": "9836", 
        "brief_summary": {
            "textblock": "This is a Post-Marketing Surveillance study of Abilify\u00ae tablets in accordance with Korean\n      regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA\n      Notification No. 2010-94 dated 27 December 2010)."
        }, 
        "brief_title": "ABF Tourette's Disorder PMS", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Tourette's Disorder", 
        "condition_browse": {
            "mesh_term": "Tourette Syndrome"
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted in a prospective, single-arm, multi-center format. As this\n      study is observational in nature, the patient's follow-up is not prescriptive in nature and\n      must be left up to the judgment of the physician (investigator), within the period of\n      observation set forth in the protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pediatric patients 6 to 18 years of age with Tourette's Disorder\n\n          -  Patients who are prescribed Abilify\u00ae treatment as per investigator's medical\n             judgment.\n\n          -  Patients who gave written authorization to use their personal and health data\n\n          -  Patients starting Abilify\u00ae treatment after agreement is in place\n\n        Exclusion Criteria:\n\n          -  Patients with known hypersensitivity to Aripiprazole  or any excipients of Abilify\u00ae\n\n          -  Patients who have been treated with Abilify\u00ae\n\n          -  Patients with rare hereditary problems of galactose intolerance, the lapp lactase\n             deficiency, or glucose-galactose malabsorption\n\n          -  Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the TS-CGI-S\n\n          -  Patients participating in other clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Pediatric patients 6 to 18 years of age with Tourette's Disorder according to the approved\n        product market authorization"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795105", 
            "org_study_id": "031-KOA-1101n"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2013", 
        "location": [
            {
                "contact": {
                    "email": "soulfree@inha.ac.kr", 
                    "last_name": "Jeong-Seop Lee, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inha University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jeong-Seop Lee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ptaewon@jbnu.ac.kr", 
                    "last_name": "Tae Won Park, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Jeonju", 
                        "country": "Korea, Republic of", 
                        "zip": "561-712"
                    }, 
                    "name": "Chonbuk National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Tae Won Park", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "soochurl@snu.ac.kr", 
                    "last_name": "Soo Churl Cho, Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Soo Churl Cho", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post-Marketing Surveillance of Safety and Efficacy of Abilify\u00ae Tablets in Korean Patients With Tourette's Disorder Under the \"New Drug Re-Examination\"", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency (n) and Percentage(%) of subjects with Adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "Follow-up at least once from baseline to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Mean change in the TS-CGI from baseline to next visit(at least 6, 12 weeks interval  from baseline) post-treatment", 
            "measure": "Mean change in the TS-CGI", 
            "safety_issue": "No", 
            "time_frame": "at least 6, 12 weeks interval  from baseline"
        }, 
        "source": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2013"
    }
}